Overview: HLA-DQB106:02 TestIntroduction: The HLA-DQB106:02 Test tests for HLA-DQB106:02 allele to assess risk for narcolepsy or autoimmune diseases, helping diagnose conditions causing excessive sleepiness or immune issues. Affecting 1 in 2,000 people with narcolepsy, this allele poses diagnostic challenges due to genetic complexity. Following 2023 American Academy of Sleep Medicine (AASM) guidelines, it uses PCR for high accuracy, supporting molecular pathology screening. This test is essential for risk assessment, diagnosis, and improving outcomes in neurology.
Other Names: HLA-DQB106:02 Allele Test, Narcolepsy Risk Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: HLA typing began in the 1980s with research by Mignot, who linked HLA-DQB106:02 to narcolepsy. PCR advancements in the 2000s by Applied Biosystems improved detection, surpassing earlier serology methods.
Purpose: Detects HLA-DQB106:02 allele to assess narcolepsy risk, guides supportive therapy, and evaluates patients with sleepiness, aiming to manage symptoms.
Test Parameters: HLA-DQB106:02 allele presence
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of sleep disorders.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document excessive sleepiness or immune issues. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cataplexy), and sample collection risks.
Procedural Considerations: Uses PCR to detect alleles, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive allele indicates risk, guiding management. Early intervention might improve outcomes, while negative results may require sleep studies.
Specialist Consultation: Consult a neurologist or sleep specialist for interpretation.
Additional Supporting Tests: Polysomnography, MSLT, or autoimmune panel to confirm diagnosis.
Test Limitations: Indicates risk only; correlation with symptoms needed. False negatives possible with other alleles.
References: AASM Guidelines, 2023; Sleep, Mignot E, 2022.
